Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
Open Access
- 26 October 2020
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 56 (3) , 250-260
Abstract
Background: Fibroblast growth factor receptor 2(FGFR2) rearrangement is expected to be a novel therapeutic target in advanced/recurrent biliary tract cancer (BTC). However, efficient detection and the exact frequency ofFGFR2rearrangements among patients with advanced/recurrent BTC have not been determined, and the clinical characteristics ofFGFR2rearrangement-positive patients have not been fully elucidated. We aimed to determine the frequency ofFGFR2rearrangement-positive patients among those with advanced/recurrent BTC and elucidate their clinicopathological characteristics.Methods: Paraffin-embedded tumor samples from formalin-fixed surgical or biopsy specimens of patients with advanced/recurrent BTC were analyzed for positivity ofFGFR2rearrangement by fluorescent in situ hybridization (FISH). RNA sequencing was performed on samples from all FISH-positive and part of FISH-negative patients.Results: A total of 445 patients were enrolled. FISH was performed on 423 patients (272 patients with intrahepatic cholangiocarcinoma (ICC), 83 patients with perihilar cholangiocarcinoma (PCC), and 68 patients with other BTC). Twenty-one patients with ICC and four patients with PCC were diagnosed asFGFR2-FISH positive. Twenty-three of the 25 FISH-positive patients (20 ICC and 3 PCC) were recognized asFGFR2rearrangement positive by targeted RNA sequencing. Younger age (≤ 65 years;p = 0.018) and HCV Ab- and/or HBs Ag-positivity (p = 0.037) were significantly associated with the presence ofFGFR2rearrangement (logistic regression).Conclusions: FGFR2rearrangement was identified in ICC and PCC patients, and was associated with younger age and history of hepatitis viral infection.Keywords
Funding Information
- Ministry of Health, Labour and Welfare (Research on the establishment of treatment for biliary tract cancer, Clinical Trial on Development of New Drugs and Medical Devices)
- Ministry of Education, Culture, Sports, Science and Technology (18K07956)
- the National Cancer Center Research and Development Fund (23-A-15)
This publication has 28 references indexed in Scilit:
- Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinomaCurrent Opinion in Gastroenterology, 2015
- Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision makingOncoTargets and Therapy, 2015
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic ImplicationsPLOS ONE, 2014
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinomaHuman Pathology, 2014
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Hepatitis B virus infection increases the risk of cholangiocarcinoma: A meta‐analysis and systematic reviewJournal of Gastroenterology and Hepatology, 2012
- Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinomaJournal of Hepatology, 2012
- Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in CancerClinical Cancer Research, 2012
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 IsoformJournal of Biological Chemistry, 2009